Phio Pharmaceuticals Corp./$PHIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
- Ticker
- $PHIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- King of Prussia, United States
- Website
- phiopharma.com
PHIO Metrics
BasicAdvanced
$9.4M
-
-$1.33
-
-
Price and volume
Market cap
$9.4M
52-week high
$1.88
52-week low
$0.75
Average daily volume
75K
Financial strength
Current ratio
4.194
Quick ratio
3.934
Profitability
EBITDA (TTM)
-15.232
Management effectiveness
Return on assets (TTM)
-83.46%
Return on equity (TTM)
-158.97%
Valuation
Price to book
1.13
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
-0.726
Free cash flow yield (TTM)
-137.70%
Free cash flow per share (TTM)
-1.12
Growth
Earnings per share change (TTM)
-34.31%
3-year earnings per share growth (CAGR)
-72.65%
PHIO Financial Performance
Revenues and expenses
PHIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Newsfile Corp6 days ago
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Newsfile Corp1 week ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile Corp3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.